MarginsXMarginsX
Home › Markets › Health Care › SYRE

Spyre Therapeutics Inc. (SYRE)

SYRE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$99.37
-4.45% on the day
Market cap
$9.4B
Mid cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$155.2M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1636282/000163628226000020/0001636282-26-000020-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSYRE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2016
SEC CIK0001636282
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$155.2M
Operating income-$209.6M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$85.7M
Total assets$777.8M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
4.0 months
$82.7M cash at September 30, 2026
Share count, 1 year
+22.4%
2025-10-29 to 2026-10-27 · +2245.5% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$436.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$82.7M cash; operating cash flow -$62.3M a quarter.Report 2026-09-30
Shares outstanding94,969,184 (2026-10-27); 77,592,130 a year earlier; 4,048,927 three years earlier.Cover page 2026-10-27
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-10-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Diego, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $436.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$96.1M-$77.5M$82.7MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q2 2026
2026-06-30
Not filed-$36.2M-$69.9M$162.0MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q1 2026
2026-03-31
Not filed-$69.0M-$57.4M$97.2MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q4 2025
2025-12-31
Not filed-$62.5M-$44.6M$85.7MNo debt tags$010-K 2026-02-19
Q3 2025
2025-09-30
Not filed-$11.2M-$37.1M$64.9MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q2 2025
2025-06-30
Not filed-$36.7M-$46.6M$81.7MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q1 2025
2025-03-31
Not filed-$44.8M-$41.0M$48.5MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q4 2024
2024-12-31
$0-$56.3M-$37.2M$89.4MNo debt tags$010-K 2026-02-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-06
Latest annual report10-K2026-02-19
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-10

Source: SEC EDGAR submissions feed, 823 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.1%
1 month+29.3%
3 months+2.1%
Year to date+217.5%
1 year+359.6%
From 52-week high-4.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SMMTSummit Therapeutics Inc. Common Stock$11.82-16.47%$9.5B
TGTXTG Therapeutics Inc.$62.76-2.71%$9.5B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B
PRAXPraxis Precision Medicines Inc.$310.27-5.44%$8.7B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B
BMRNBioMarin Pharmaceutical Inc.$57.99+1.33%$11.2B
ALKSAlkermes plc$46.53-1.06%$7.8B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier